• ChemFaces is a professional high-purity natural products manufacturer.
  • Product Intended Use
  • 1. Reference standards
  • 2. Pharmacological research
  • 3. Inhibitors
  • Home
  • Natural Products
  • Bioactive
  • Screening Libraries
  • Hot Products
  • Plant Catalog
  • Customer Support
  • Product Use Citation
  • About Us
  • Contact Us
  • Natural Products
    CAS No. 20633-67-4 Price $128 / 20mg
    Catalog No.CFN99141Purity>=98%
    Molecular Weight446.40Type of CompoundFlavonoids
    FormulaC22H22O10Physical DescriptionPowder
    Download Manual    COA    MSDSSimilar structuralComparison (Web)
    Citing Use of our Products
    How to Order
    Orders via your E-mail:

    1. Product number / Name / CAS No.
    2. Delivery address
    3. Ordering/billing address
    4. Contact information
    Sent to Email: info@chemfaces.com
    Contact Us
    Order & Inquiry & Tech Support

    Tel: (0086)-27-84237683
    Fax: (0086)-27-84254680
    E-mail: manager@chemfaces.com
    Address: No. 83, CheCheng Rd., WETDZ, Wuhan, Hubei 430056, PRC
    Delivery time
    Delivery & Payment method

    1. Usually delivery time: Next day delivery by 9:00 a.m. Order now

    2. We accept: Wire transfer & Credit card & Paypal & Western Union
    * Packaging according to customer requirements(5mg, 10mg, 20mg and more). We shipped via FedEx, DHL, UPS, EMS and others courier.
    According to end customer requirements, ChemFaces provide solvent format. This solvent format of product intended use: Signaling Inhibitors, Biological activities or Pharmacological activities.
    Size /Price /Stock 10 mM * 1 mL in DMSO / $54.1 / In-stock
    Other Packaging *Packaging according to customer requirements(100uL/well, 200uL/well and more), and Container use Storage Tube With Screw Cap
    Our products had been exported to the following research institutions and universities, And still growing.
  • University of Malaya (Malaysia)
  • University of Medicine and Phar... (Romania)
  • Semmelweis Unicersity (Hungary)
  • Universidade do Porto (Portugal)
  • Universidad Miguel Hernández (Spain)
  • Complutense University of Madrid (Spain)
  • University of Fribourg (Switzerland)
  • Worcester Polytechnic Institute (USA)
  • Universit?t Basel (Switzerland)
  • Mahatma Gandhi University (India)
  • Centralised Purchases Unit (CPU... (India)
  • More...
  • Package
    Featured Products

    Catalog No: CFN92163
    CAS No: 119400-86-1
    Price: $595/5mg
    Alisol C

    Catalog No: CFN92545
    CAS No: 30489-27-1
    Price: $388/5mg

    Catalog No: CFN99710
    CAS No: 51059-44-0
    Price: $100/20mg

    Catalog No: CFN92425
    CAS No: 86361-55-9
    Price: $218/5mg
    Kaempferol 3-O-(6''-galloyl)-beta-...

    Catalog No: CFN92383
    CAS No: 56317-05-6
    Price: $533/5mg
    Ginsenoside Rh3

    Catalog No: CFN99972
    CAS No: 105558-26-7
    Price: $218/20mg
    3-O-Caffeoylquinic acid methyl ester

    Catalog No: CFN92573
    CAS No: 123483-19-2
    Price: $198/10mg
    Related Screening Libraries
    Size /Price /Stock 10 mM * 100 uL in DMSO / Inquiry / In-stock
    10 mM * 1 mL in DMSO / Inquiry / In-stock
    Related Libraries
  • Antioxidants Compound Library
  • Anti-cerebral ischemia Compound Library
  • Anti-apoptotic Compound Library
  • Flavonoids Compound Library
  • VEGFR Inhibitor Library
  • ROS Inhibitor Library
  • ROCK Inhibitor Library
  • Rho Inhibitor Library
  • PI3K Inhibitor Library
  • NO Inhibitor Library
  • MMP(e.g.TIMP) Inhibitor Library
  • Caspase Inhibitor Library
  • Bcl-2/Bax Inhibitor Library
  • Akt Inhibitor Library
  • Biological Activity
    Description: Calycosin-7-O-beta-D-glucoside, a melanin biosynthesis inhibitor, can protect BBB integrity in experimental cerebral ischemia–reperfusion injury via regulating NO/cav-1/MMPs pathway. It attenuates ischemia-reperfusion injuryin vivovia activation of the PI3K/Akt pathway, and has effects on cell apoptosis in cervical cancer HeLa cells and expression of Bcl-2/Bax.
    Targets: NO | MMP(e.g.TIMP) | Bcl-2/Bax | PI3K | VEGFR | Akt | Rho | ROCK | Caspase | ROS
    In vitro:
    Bmc Compl. Altern. M., 2015, 15(1):1-11.
    Calycosin-7-O-β-D-glucoside promotes oxidative stress-induced cytoskeleton reorganization through integrin-linked kinase signaling pathway in vascular endothelial cells.[Pubmed: 26346982 ]
    Dysfunction of vascular endothelium is implicated in many pathological situations. Cytoskeleton plays an importance role in vascular endothelial permeability barrier and inflammatory response. Many Chinese herbs have the endothelial protective effect, of which, "Astragalus membranaceus" is a highly valued herb for treatment of cardiovascular and renal diseases in traditional Chinese medicine, In this study, we tested whether calycosin-7-O-β-D-glucoside (Calycosin), a main effective monomer component of "Astragalus membranaceus", could protect endothelial cells from bacterial endotoxin (LPS)-induced cell injury.
    Endothelial cell injury was induced by exposing human umbilical vein endothelial cells (HUVECs) to LPS. The effects of calycosin on LPS-induced changes in cell viability, apoptosis rate, cell migration, nitric oxide synthase (NOS), generationof intracellular reactive oxygen species (ROS) and cytoskeleton organization were determined. Microarray assay was employed to screen the possible gene expression change. Based on the results of microarray assay, the expression profile of genes involved in Rho/ROCK pathway and AKT pathway were further evaluated with quantitative real-time RT-PCR or western blot methods. Calycosin improved cell viability, suppressed apoptosis and protected the cells from LPS-induced reduction in cell migration and generation of ROS, protein level of NOS at a comparable magnitude to that of Y27632 and valsartan. Similar to Y27632 and valsartan, Calycosin, also neutralized LPS-induced actomyosin contraction and vinculin protein aggregation. Microarray assay, real-time PCR and western blot results revealed that LPS induced expression of FN, ITG A5, RhoA, PI3K (or PIP2 in western blotting), FAK, VEGF and VEGF R2, and inhibited expression of MLCP. We believed multiple pathways involved in the regulation of calycosin on HUVECs. Calycosin are considered to be able to activate MLCP through promoting the generation of NO, decreasing PMLC, suppressing the cytoskeleton remodeling caused by activation of Rho/ROCK pathway and inhibiting AKT pathway by decreasing VEGF, VEGF R2 and PI3K level.
    Calycosin protected HUVEC from LPS-induced endothelial injury, possibly through suppression of Rho/ROCK pathway and regulation of AKT pathway.
    In vivo:
    Mol Med Rep. 2016 Jan; 13(1): 633–640.
    Calycosin-7-O-β-d-glucoside attenuates ischemia-reperfusion injury in vivo via activation of the PI3K/Akt pathway[Pubmed: 26648122]
    The aim of the present study was to investigate the effects and mechanisms of calycosin‑7‑O‑β‑D‑glucoside (CG) on ischemia‑reperfusion (I/R) injury in vivo.
    Hemodynamic parameters, including ejection fraction (EF), fractional shortening (FS), left ventricular end‑systolic pressure (LVESP) and left ventricular end‑diastolic pressure (LVEDP) were monitored using an ultrasound system, and infarct size was measured using Evans blue/tetrazolium chloride double staining. The activities of serum creatine kinase (CK), lactate dehydrogenase (LDH) and superoxide dismutase (SOD), and the levels of malondialdehyde (MDA) were determined to assess the degree of myocardial injury and oxidative stress‑induced damage. The protein expression levels of cleaved‑caspase‑3, cleaved‑caspase‑9, phosphorylated (p)‑phosphatidylinositol 3‑kinase (PI3K) p85, PI3K p85, p‑Akt and Akt were determined using western blotting. The results demonstrated that pretreatment with high dose (H)‑CG markedly improved cardiac function, as evidenced by upregulated EF, FS and LVESP, and downregulated LVEDP. In addition, administration of CG resulted in significant decreases in infarct size in the I/R+low dose‑CG and I/R+H‑CG groups, compared with the I/R group. The activities of CK and LDH, and the levels of MDA in the I/R+H‑CG group were reduced, compared with those in the I/R group, whereas SOD activity was elevated. Treatment with CG inhibited the cleavage and activity of caspase‑3 and caspase‑9, and enhanced the phosphorylation of PI3K p85 and Akt. Notably, administration of the PI3K inhibitor, LY294002, markedly lowered the levels of p‑PI3K p85/p‑Akt, and eradicated the inhibitory effects of H‑CG on infarct size, myocardial injury and oxidative stress‑induced damage.
    Taken together, the results suggested that CG may alleviate I/R injury by activating the PI3K/Akt signaling pathway.
    Calycosin-7-O-beta-D-glucoside Description
    Source: The herbs of Astragalus membranaceus Bge. var. mongholicus.
    Solvent: DMSO, Pyridine, Methanol, Ethanol, etc.
    Storage: Providing storage is as stated on the product vial and the vial is kept tightly sealed, the product can be stored for up to 24 months(2-8C).

    Wherever possible, you should prepare and use solutions on the same day. However, if you need to make up stock solutions in advance, we recommend that you store the solution as aliquots in tightly sealed vials at -20C. Generally, these will be useable for up to two weeks. Before use, and prior to opening the vial we recommend that you allow your product to equilibrate to room temperature for at least 1 hour.

    Need more advice on solubility, usage and handling? Please email to: service@chemfaces.com

    After receiving: The packaging of the product may have turned upside down during transportation, resulting in the natural compounds adhering to the neck or cap of the vial. take the vial out of its packaging and gently shake to let the compounds fall to the bottom of the vial. for liquid products, centrifuge at 200-500 RPM to gather the liquid at the bottom of the vial. try to avoid loss or contamination during handling.
    Recent ChemFaces New Products and Compounds

    Catalog No: CFN95180
    CAS No: 27062-01-7
    Price: $318/10mg
    Brevilin A

    Catalog No: CFN99694
    CAS No: 16503-32-5
    Price: $218/10mg
    Neochlorogenic acid

    Catalog No: CFN97472
    CAS No: 906-33-2
    Price: $138/20mg
    Arteannuin B

    Catalog No: CFN98807
    CAS No: 50906-56-4
    Price: $228/20mg
    Aristolochic acid C

    Catalog No: CFN90516
    CAS No: 4849-90-5
    Price: $318/10mg
    Arjunic acid

    Catalog No: CFN98397
    CAS No: 31298-06-3
    Price: $318/5mg

    Catalog No: CFN95213
    CAS No: 119240-82-3
    Price: $413/5mg

    Catalog No: CFN97083
    CAS No: 62596-29-6
    Price: $128/20mg
    Recently, ChemFaces products have been cited in many studies from excellent and top scientific journals

    Cell. 2018 Jan 11;172(1-2):249-261.e12.
    doi: 10.1016/j.cell.2017.12.019.

    PMID: 29328914

    Cell Metab. 2020 Mar 3;31(3):534-548.e5.
    doi: 10.1016/j.cmet.2020.01.002.

    PMID: 32004475

    Mol Cell. 2017 Nov 16;68(4):673-685.e6.
    doi: 10.1016/j.molcel.2017.10.022.

    PMID: 29149595

    ACS Nano. 2018 Apr 24;12(4): 3385-3396.
    doi: 10.1021/acsnano.7b08969.

    PMID: 29553709

    Nature Plants. 2016 Dec 22;3: 16206.
    doi: 10.1038/nplants.2016.205.

    PMID: 28005066

    Sci Adv. 2018 Oct 24;4(10): eaat6994.
    doi: 10.1126/sciadv.aat6994.

    PMID: 30417089
    Calculate Dilution Ratios(Only for Reference)
    1 mg 5 mg 10 mg 20 mg 25 mg
    1 mM 2.2401 mL 11.2007 mL 22.4014 mL 44.8029 mL 56.0036 mL
    5 mM 0.448 mL 2.2401 mL 4.4803 mL 8.9606 mL 11.2007 mL
    10 mM 0.224 mL 1.1201 mL 2.2401 mL 4.4803 mL 5.6004 mL
    50 mM 0.0448 mL 0.224 mL 0.448 mL 0.8961 mL 1.1201 mL
    100 mM 0.0224 mL 0.112 mL 0.224 mL 0.448 mL 0.56 mL
    * Note: If you are in the process of experiment, it's need to make the dilution ratios of the samples. The dilution data of the sheet for your reference. Normally, it's can get a better solubility within lower of Concentrations.
    Cell Research:
    Chinese Traditional & Herbal Drugs, 2015, 46(10):1498-502.
    Effects of calycosin-7-O-β-D-glucoside on cell apoptosis in cervical cancer HeLa cells and expression of Bcl-2/Bax[Reference: WebLink]
    To explore the effect of Calycosin-7-O-beta-D-glucoside (CG) on apoptosis in cervical cancer HeLa cells and expression of Bcl-2/Bax.
    HeLa cells were cultured and divided into two groups, including control group and experimental group. Cell viabilities were determined by the MTT method; Apoptosis and cell cycle were analyzed by flow cytometry; The changes of protein expression of cleaved Caspase-3, Bcl-2, and Bax were detected by Western blotting. From the data of MTT, the cell proliferation of human cervical cancer HeLa cells was inhibited by CG (2.5-100 μg/mL) in a dose- and time-dependent manner. Flow cytometry assays showed that EGCG significantly induced the apoptosis in HeLa cells. The apoptosis rate of the experimental group were increased gradually in 48 h after treated with CG (20, 40, and 80 μg/mL), they were 10.40%, 25.50%, and 39.40%, respectively, significantly higher than those in the control group. The data of Western blotting showed that CG down-regulated Bcl-2 and up-regulated cleaved Caspase-3 and Bax in a dose-dependent manner.
    CG could inhibit the the proliferation of HeLa cells and promote apoptosis, and the anticancer effect of CG may be associated with the down-regulation of Bcl-2 expression and up-regulation of Bax expression, as well as the increase of relative activity of Caspase-3. CG may be a promising antitumor agent for cancer treatment.
    Animal Research:
    J Ethnopharmacol. 2014 Aug 8;155(1):692-701.
    Calycosin-7-O-β-D-glucoside regulates nitric oxide /caveolin-1/matrix metalloproteinases pathway and protects blood-brain barrier integrity in experimental cerebral ischemia-reperfusion injury.[Pubmed: 24930357]
    Astragali Radix (AR) has been used for thousands years to treat ischemic stroke. Calycosin and its glycoside form Calycosin-7-O-beta-D-glucoside(CG) are two representative isoflavones in Astragali Radix. However, its neurological effects and related molecular mechanisms are largely unknown. The present study aims to evaluate the neuroprotective effects of CG on blood-brain barrier (BBB) integrity of ischemic brain tissue and explore the relevant signaling mechanisms.
    Male adult Sprague-Daweley rats were subjected to 2 h of middle cerebral artery occlusion (MCAO) plus 24 h or 14 days of reperfusion. CG (26.8 mg/kg) was intraperitoneally administered into the rats at 15 min before onset of ischemia. The neuroprotective effects of CG were evaluated by measuring infarct volume, histological damage and BBB permeability. Furthermore, the effects of CG on scavenging nitric oxide (NO), and modulating matrix metalloproteinases (MMPs) and caveolin-1 (cav-1) were investigated with in vitro cultured brain microvascular endothelial cells treated with NO donor or oxygen-glucose deprivation (OGD) and/or in vivo rat model of MCAO cerebral ischemia-reperfusion injury. CG treatment significantly reduced infarct volume, histological damage and BBB permeability in the in vivo MCAO ischemia-reperfusion rat model. CG treatment remarkably inhibited the expression and activities of MMPs, and secured the expression of cav-1 and tight junction proteins in the microvessels isolated from ischemic rat cortex. Furthermore, CG was revealed to scavenge NO, inhibit the activities of MMP-2 and MMP-9, and attenuate cell death in the in vitro cultured brain microvascular endothelial cells under OGD condition.
    CG could protect BBB integrity in experimental cerebral ischemia-reperfusion injury via regulating NO/cav-1/MMPs pathway.